Combinatorial immunotherapy may improve the efficacy of neoadjuvant checkpoint inhibitors in locoregionally advanced melanoma. In this issue of Cancer Cell, Davar and colleagues report a promising phase 2 neoadjuvant trial of the TLR9 agonist vidutolimod in combination with nivolumab. Analyses suggest a unique myeloid expression signature is associated with response.

中文翻译：

---

瘤内 vidutolimod 联合 PD-1 阻断治疗局部晚期黑色素瘤


组合免疫疗法可能会提高新辅助检查点抑制剂在局部晚期黑色素瘤中的疗效。在本期《癌细胞》中，Davar 及其同事报告了一项有前景的 TLR9 激动剂 vidutolimod 联合纳武利尤单抗的 2 期新辅助试验。分析表明，独特的髓系表达特征与反应相关。